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OBJECTIVES We sought to determine whether serum tumor necrosis factor-alpha (TNF-alpha) levels are
elevated in patients with hemodynamically significant pressure and volume overload.
BACKGROUND It has been previously shown that TNF-alpha messenger ribonucleic acid (mRNA) and
protein are rapidly expressed in the hearts of animal models subjected to abrupt hemodynamic
overloading. The clinical significance of these experimental findings has not been tested in
pathophysiologically relevant clinical models in human subjects.
METHODS We prospectively measured serum TNF-alpha levels and serum TNF receptor 1 and 2 levels
in 21 patients with severe aortic stenosis (AS), in 26 patients with 31 to 41 mitral
regurgitation (MR) and in normal age- and gender-matched control subjects. Patients with
AS and MR were either in New York Heart Association (NYHA) functional class I or II and
had no significant coronary disease. We compared the cytokine levels among the groups using
analysis of variance. We related cytokine levels to the severity of AS using simple regression
analysis.
RESULTS Serum TNF-alpha levels in patients with AS (2.1 6 1.6 pg/ml, n 5 21) and MR (1.3 6
0.7 pg/ml, n 5 26) were significantly higher than those in the control subjects (0.7 6
0.2 pg/ml, n 5 28). Serum TNF receptor 1 and 2 levels were also higher in patients with AS
and MR than in control subjects. Cytokine levels were higher in patients in NYHA class II
than in those in class I. In patients with a normal ejection fraction (.50%, n 5 16), there was
a mild positive correlation (r 5 0.56, p 5 0.025) between serum TNF-alpha levels and the
mean gradient across the aortic valve.
CONCLUSIONS This study demonstrates that serum TNF-alpha is elevated in patients with chronic
hemodynamic overloading and early cardiac decompensation. Furthermore, these findings
suggest not only that peripheral TNF-alpha levels correlate with the severity of the
hemodynamic pressure overload, but also that peripheral TNF-alpha and TNF receptor levels
increase in direct relation to deteriorating NYHA functional class. (J Am Coll Cardiol 2000;
36:208–12) © 2000 by the American College of Cardiology
There is increasing evidence that the progressive elaboration
of tumor necrosis factor-alpha (TNF-alpha) may play a role
in the cardiac decompensation that ensues in a variety of
cardiac disease states (1–5). Although TNF-alpha was
initially described as a myocardial depressant substance in
patients with septic shock, elevation of this cytokine has
subsequently been demonstrated in a variety of cardiac
disease states, including those of patients with symptomatic
heart failure (6,7). When overexpressed, TNF-alpha can
exert direct toxic effects on the heart and the peripheral
circulation, and thus may potentially explain some of the
structural and functional changes that are observed in
cardiac decompensation. Indeed, overexpression of TNF-
alpha has been shown to lead to left ventricular (LV)
dysfunction and LV remodeling in animal models with
long-term infusion of TNF-alpha, as well as in transgenic
animals with targeted cardiac overexpression (1,2,8).
In the natural history of valvular heart disease, there is a
phase of compensatory hypertrophy followed by progressive
cardiac decompensation. However, the exact mechanisms
that are responsible for the development of cardiac decom-
pensation after hemodynamic overloading remain unknown.
Relevant to this discussion is the experimental observation
that hemodynamic overloading and myocardial stretch are
sufficient to provoke de novo TNF-alpha messenger ribo-
nucleic acid (mRNA) and protein expression in the heart
(9,10). However, the clinical significance of these early
experimental studies is not known. Accordingly, the pur-
pose of this study was to prospectively study TNF-alpha and
TNF receptor levels in patients with clinically significant
aortic stenosis (AS) or mitral regurgitation (MR).
METHODS
Patient group. We prospectively enrolled patients with an
echocardiographic diagnosis of either significant AS (aortic
From the Cleveland Clinic Foundation, Cleveland, Ohio; and *Winters Center for
Heart Failure Research, Baylor College of Medicine and Veterans Affairs Medical
Center, Houston, Texas.
Manuscript received July 22, 1999; revised manuscript received January 20, 2000,
accepted March 27, 2000.
Journal of the American College of Cardiology Vol. 36, No. 1, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)00721-X
valve area [AVA] #1.0 cm2) or significant MR (31 to 41),
who had mild symptoms (New York Heart Association
[NYHA] functional class I or II). The severity of MR was
determined semiquantitatively by using the regurgitant jet
length, width and direction on color Doppler echocardiog-
raphy (11). Every patient had cardiac catheterization within
six months of enrollment, and patients with coronary artery
stenosis .50% were excluded. Patients with diseases asso-
ciated with raised serum TNF-alpha, such as recent endo-
carditis (within six months), active malignancies, infection,
connective tissue disorders and fever, were excluded. Pa-
tients with complex multivalvular lesions were excluded. For
the control group, middle-aged (55 6 8 years old, n 5 28,
including 16 [57%] men) normal subjects with no signifi-
cant illness were used.
Serum cytokine measurements. Blood was collected in a
nonheparinized glass tube from a forearm vein. Blood was
stored on ice immediately after collection, and within
15 min serum was separated by standard centrifugation at
1,500 rpm for 10 min. Serum was immediately separated
and stored at 270°C until the assay. Cytokine measure-
ments were performed in a core laboratory by scientists who
had no knowledge of the clinical information. Commer-
cially available enzyme-linked immunosorbent assay kits
(Quantikine HS, R&D Systems) were used for measure-
ment of TNF-alpha and TNF receptors 1 and 2, exactly as
described previously (4).
Clinical data collection. The clinical information was
collected prospectively before the assessment of peripheral
levels of cytokine and cytokine receptors. The patients’
functional class was determined on the basis of the clinical
history, as well as from chart review. Echocardiography was
performed in the research echocardiography laboratory at
the Cleveland Clinic. M-mode, two-dimensional and Dopp-
ler echocardiographic measurements were made on-line by
independent observers who had no knowledge of the clinical
history. We took end-diastolic measurements of posterior
wall and intraventricular septal thickness and end-systolic
and end-diastolic measurement of LV diameter, left atrial
diameter, ejection fraction (EF) by Simpson’s rule and LV
mass measurement by the Penn Convention (12,13). Con-
tinuous wave Doppler echocardiography was used to mea-
sure the severity of AS. Peak and mean gradients, as well as
AVA, using the continuity equation, were calculated for
each patient. As previously described, the severity of MR
was assessed semiquantitatively by color flow mapping (14)
and by analysis of pulmonary venous flow (15–17). Only
patients with significant MR ($31) were included in the
study.
Statistical analysis. Data are expressed as the mean
value 6 SD. Continuous variables were compared using the
unpaired, two-tailed Student t test. When comparing con-
tinuous variables among multiple groups, analysis of vari-
ance, with post hoc analysis using the Newman-Keuls test,
was employed. Simple linear regression analysis was per-
formed to study the relation between continuous variables.
Multiple regression analysis was performed to determine
whether the presence of AS and MR was associated with
higher TNF-alpha levels independent of age and gender.
RESULTS
Patient group. We studied 47 mildly symptomatic patients
with either AS or MR. Of these 47 patients, 21 had severe
AS and 26 had severe MR. The clinical characteristics of
these patients are listed in Table 1. Patients with AS were
significantly older as compared with patients with MR. The
use of angiotensin-converting enzyme inhibitors, digoxin
and diuretics for each group are summarized in Table 1. The
echocardiographic characteristics are listed in Table 2. The
EF was reduced to ,50% in five patients with AS and in
one patient with MR.
Circulating levels of TNF-alpha and TNF receptors.
Serum TNF-alpha levels in patients with AS and MR were
significantly higher than those levels in the control group
(Fig. 1). Patients with AS had significantly higher (p ,
0.05) TNF-alpha levels than did patients with MR. Even
Abbreviations and Acronyms
AS 5 aortic stenosis
AVA 5 aortic valve area
CI 5 confidence interval
EF 5 ejection fraction
LV 5 left ventricular
mRNA 5 messenger ribonucleic acid
MR 5 mitral regurgitation
NYHA 5 New York Heart Association
OR 5 odds ratio
TNF-alpha 5 tumor necrosis factor-alpha











Age (yrs) 71 6 12 56 6 13 0.0004
Male gender 13 (62%) 17 (65%) NS
Hypertension 13 (68%) 21 (81%) NS
Diabetes mellitus 3 (17%) 1 (4%) NS
Smoking 10 (56%) 7 (27%) NS
History of AF 3 (15%) 8 (30%) NS
NYHA class I 6 (29%) 12 (46%) NS
SBP/DBP (mm Hg) 133 6 15/75 6 8 119 6 31/73 6 20 NS
Serum sodium
(mEq/liter)
139 6 3 141 6 2 NS
Serum BUN (mg/dl) 18 6 7 16 6 4 NS
Serum creatinine (mg/dl) 1.0 6 0.2 0.9 6 0.2 NS
WBC count (103/mm3) 7 6 2 6 6 1 NS
Medications
ACE inhibitors 3 (14%) 7 (27%) NS
Digoxin 6 (28%) 6 (23%) NS
Diuretics 2 (10%) 8 (31%) NS
Data are presented as the mean value 6 SD or number (%) of patients.
ACE 5 angiotensin-converting enzyme; AF 5 atrial fibrillation; BUN 5 blood
urea nitrogen; DBP 5 diastolic blood pressure; NS 5 not significant; NYHA 5 New
York Heart Association; SBP 5 systolic blood pressure; WBC 5 white blood cell.
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when patients in NYHA class I were analyzed, the TNF-
alpha levels in patients with AS were higher than those in
patients with MR (Table 3). In a multiple regression
analysis, the presence of AS (odds ratio [OR] 1.4, 95%
confidence interval [CI] 1.13 to 1.85) and MR (OR 1.2,
95% CI 1.03 to 1.55) predicted higher TNF-alpha levels,
even after adjusting for the age differences. Interestingly, in
patients with AS with preserved ventricular function (EF
.50%, n 5 16), there was a modest positive correlation (r 5
0.56, p 5 0.025) between peripheral levels of TNF-alpha
level and the mean gradient across the aortic valve (Fig. 2).
The circulating levels of soluble TNF receptors were also
significantly higher in patients with AS than in the control
subjects (p 5 0.001 for both) (Fig. 3A). However, in
patients with MR, TNF receptors 1 and 2 were only
minimally elevated and were not statistically different from
those in control subjects (p 5 0.11 and p 5 0.18, respec-
tively) (Fig. 3B). For patients with AS and MR, TNF
receptors 1 and 2 were significantly higher in patients in
NYHA class II than in patients in NYHA class I (Table 4).
Finally, there was a modest correlation between the serum
level of TNF receptors 1 and 2 and the mean gradient across
the aortic valve (r 5 0.44, p 5 0.047 and r 5 0.43, p 5 0.05,
respectively).
DISCUSSION
This study shows that circulating levels of TNF-alpha are
elevated in patients with clinically significant hemody-
namic pressure and volume overload. Moreover, it sug-
gests not only that the peripheral TNF-alpha levels
correlate with the severity of the hemodynamic pressure
overload (Fig. 2), but also that the peripheral TNF-alpha
and TNF receptor levels increase in direct relation to
deteriorating NYHA functional classification (Tables 3
and 4). One of the more interesting, albeit unexpected,
findings of this study was that patients with chronic
pressure overload had higher serum TNF-alpha and TNF
receptor (receptors 1 and 2) levels than did patients with
chronic volume overload, thus suggesting that pressure
overload may serve as a greater stimulus for cytokine
production, as compared with volume overload. How-
ever, the precise reasons for these differences in cytokines
and cytokine receptors in patients with pressure and
volume overload are not known at this time.
Circulating levels of TNF-alpha and TNF receptors have
consistently been shown to be elevated in patients with heart
failure; moreover, the peripheral levels of these proteins
have been shown to correlate with the patients’ NYHA
Figure 1. Serum TNF-alpha levels in normal subjects (0.7 6 0.2 pg/ml,
n 5 28), in patients with AS (2.1 6 1.6 pg/ml, n 5 21) and in patients
with MR (1.3 6 0.7 pg/ml, n 5 26). Analysis of variance showed
significant differences between the groups, and a post hoc comparison
demonstrated significant differences between all three groups. Serum
TNF-alpha levels of patients with NYHA class I symptoms and control
subjects are shown by solid circles, and those levels of patients with class
II symptoms are shown by open circles.
Figure 2. Correlation between the mean gradient across the aortic valve
and serum TNF-alpha level in patients with AS and a normal (.50%) LV
ejection fraction (n 5 16). The central line represents the regression, and
the other lines show the 95% confidence levels for the regression.









Ejection fraction (%) 54 6 14 63 6 8
LV end-systolic diameter (mm) 28 6 9 35 6 5
LV end-diastolic diameter (mm) 47 6 9 62 6 7
Septal thickness (mm) 14 6 3 11 6 3
Posterior wall thickness (mm) 14 6 3 10 6 2
LA diameter (mm) 42 6 9 50 6 12
LV mass index (g/m) 186 6 59 199 6 68
Aortic valve area (cm2) 0.65 6 0.13 —
Peak/mean gradient (mm Hg) 96 6 37/57 6 21 —
Data are presented as the mean value 6 SD.
LA 5 left atrial; LV 5 left ventricular.
Table 3. Serum Tumor Necrosis Factor-Alpha Levels in
Patients With Aortic Stenosis and Mitral Regurgitation,







All patients 2.1 6 1.6 1.3 6 0.7 0.03
(n 5 21) (n 5 26)
Class I 1.7 6 0.7 0.9 6 0.5 0.02
(n 5 6) (n 5 12)
Class II 2.2 6 1.9 1.6 6 0.7 0.23
(n 5 15) (n 5 14)
Data are presented as the mean value 6 SD in pg/ml.
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functional class (4,18). However, the site and source of
cytokine production in heart failure remain unknown. Rel-
evant to this discussion is the observation that both TNF-
alpha protein and mRNA are expressed in the hearts of
patients with advanced heart failure, whereas neither TNF-
alpha protein nor mRNA are expressed in the hearts of
normal subjects (5). Although the mechanism for the
increase in TNF-alpha mRNA and protein expression is not
known, a previous study has shown that TNF-alpha mRNA
and protein are rapidly expressed in an animal model of
acute pressure overload (9). Accordingly, the positive cor-
relation between peripheral TNF-alpha levels and the mean
gradient across the aortic valve in patients with AS suggests
not only that chronic pressure overload is a relevant stimulus
for TNF-alpha expression, but also that the heart is likely to
be an important source for TNF-alpha production. Patients
with abnormal LV systolic function were excluded from this
analysis, as the pressure gradient in these patients does not
accurately reflect the severity of AS and pressure overload.
Although we observed that there was a significant in-
crease in serum TNF-alpha levels in direct relation to
deteriorating NYHA class, the results of the present study
do not distinguish whether elevated TNF-alpha levels are a
cause or effect of increasing cardiac decompensation. In-
deed, given the biologic complexity of hemodynamic over-
loading, it would be naive to suggest that any one molecule
was responsible for cardiac decompensation. This statement
notwithstanding, it bears emphasis that overexpression of
TNF-alpha in the heart has been shown to lead to progres-
sive LV remodeling, as well as progressive LV dysfunction
in experimental models (1–3). Moreover, elevated periph-
eral TNF-alpha levels might be expected to lead to inap-
propriate vasodilation by increasing endothelial nitric oxide
production, which may have overt deleterious consequences
in patients with AS. Thus, it is possible that TNF-alpha
may be one of a variety of different biologically active
molecules that contribute to the progressive cardiac decom-
pensation that occurs in sustained hemodynamic overload-
ing. Apart from the potential pathophysiologic relevance of
the present findings, the results of this study suggest that
progressively rising TNF-alpha levels may serve as a poten-
tially useful biochemical marker for progressive cardiac
decompensation in patients with valvular heart disease.
Although it is unlikely that elevated levels of TNF-alpha
will ever replace the more traditional indexes that have been
used in the timing of surgery for patients with symptomatic
valvular heart disease, it is possible that progressive increases
in TNF-alpha levels may prove to be useful in the timing of
valve replacement in patients with asymptomatic valvular
heart disease, in whom a subset of patients experience
untoward outcomes (19–23).
One of the major study limitations includes the unavail-
ability of postoperative TNF-alpha levels to verify whether
elevated cytokine levels became normalized after surgical
correction of pressure or volume overload. Immediate post-
operative levels may not be accurate, as the operation itself
Figure 3. A, Soluble TNF receptor 1 levels in normal subjects (841 6 361
pg/ml, n 5 32), in patients with AS (1,614 6 884 pg/ml, n 5 21) and in
patients with MR (1,060 6 270 pg/ml, n 5 26). Soluble TNF receptor 1
levels of patients with NYHA class I symptoms and control subjects are
shown by solid squares, and those levels of patients with class II symptoms
are shown by open squares. B, Soluble TNF receptor 2 levels in normal
subjects (2,694 6 884 pg/ml, n 5 32), in patients with AS (4,559 6 2,389
pg/ml, n 5 21) and in patients with MR (3,202 6 838 pg/ml, n 5 26).
Soluble TNF receptor 2 levels of patients with NYHA class I symptoms
and control subjects are shown by solid triangles, and those levels of
patients with class II symptoms are shown by open triangles.
Table 4. Serum Levels of Tumor Necrosis Factor Receptors in
Patients With Aortic Stenosis and Mitral Regurgitation,







All patients 1,614 6 884 1,060 6 270 0.004
(n 5 21) (n 5 26)
Class I 1,302 6 330 897 6 209 0.005
(n 5 6) (n 5 12)
Class II 1,739 6 1,010 1,199 6 241 0.06
(n 5 15) (n 5 14)
TNF-Receptor 2 (pg/ml)
All patients 4,559 6 2,389 3,201 6 838 0.010
(n 5 21) (n 5 26)
Class I 3,682 6 1,038 2,645 6 743 0.03
(n 5 6) (n 5 12)
Class II 4,910 6 2,702 3,680 6 593 0.11
(n 5 15) (n 5 14)
Data are presented as the mean value 6 SD.
TNF 5 tumor necrosis factor.
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can lead to elevated cytokine levels. Referring physicians
monitor their own patients, which makes it logistically
difficult to collect postoperative cytokine levels. Further, the
patients with AS are older than patients with MR and the
normal control subjects. Although these differences in age
between the patient groups does not completely account for
the elevated cytokine levels, the impact of aging on cytokine
production remains unknown.
Conclusions. This clinical study directly supports the hy-
pothesis that hemodynamic overloading is a sufficient stim-
ulus for TNF-alpha production in the adult human heart,
which is consistent with our previous experimental obser-
vations. Moreover, this study suggests that peripheral TNF-
alpha and TNF receptor levels increase in relation to the
patient’s worsening NYHA functional class. Given the
mechanical burden that is imposed by sustained hemody-
namic overloading, it is unlikely that modulating TNF-
alpha expression will favorably alter the natural history of
valvular heart disease. Nonetheless, it is possible that anti-
cytokine strategies might be employed as an adjunctive
therapy before operation in high risk patients with de-
pressed ventricular performance, in whom sustained ventric-
ular dysfunction may prevent immediate postoperative re-
covery. Moreover, this study raises the intriguing possibility
that serial measurements of TNF-alpha in patients with
asymptomatic valvular heart disease may help to identify
patients in the earliest stages of decompensation, who are
not diagnosed with conventional noninvasive testing. Fur-
ther studies will be necessary to address these interesting
and important possibilities.
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